文章核心观点 - 介绍Adma Biologics股票表现、盈利预期、估值等情况，提示投资者关注盈利表现和分析师估计变化 [1][2][4] 股票表现 - 最新交易日收盘价23.52美元，较上一交易日涨1.07%，表现落后于标普500指数当日涨幅1.47% [1] - 过去一个月股价涨19.64%，跑赢医疗板块跌幅2.95%和标普500指数跌幅0.47% [1] 盈利预期 - 公司定于2025年5月7日公布财报，预计每股收益0.16美元，较去年同期增长100%，预计净销售额1.191亿美元，同比增长45.46% [2] - 全年预计每股收益0.71美元，收入4.958亿美元，分别较去年变化+44.9%和+16.26% [3] 分析师估计 - 分析师估计变化反映短期业务趋势，积极修订传达对公司业务和盈利潜力的信心 [4] - Zacks Rank模型考虑估计变化并提供评级系统，Adma Biologics目前Zacks Rank为2（买入） [5][6] 估值情况 - 公司目前远期市盈率32.78，高于行业平均远期市盈率17.32 [7] - 医疗 - 生物医学和遗传学行业Zacks行业排名84，处于所有250多个行业的前35% [7]

Adma Biologics (ADMA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this infectious disease drug developer have returned +17.7% over the past month versus the Zacks S&P 500 composite's -0.7% change. The Zacks Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has lost 1.6% over this period. Now the key question is: Where could ...